A5035179518- Vasculitis and related conditions
- Patient Safety and Medication Errors
- Intravenous Infusion Technology and Safety
- Central Venous Catheters and Hemodialysis
- Genetic and Kidney Cyst Diseases
- Renal and related cancers
- Eosinophilic Esophagitis
- Renal Diseases and Glomerulopathies
- Genetic Syndromes and Imprinting
- Bone Metabolism and Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Autoimmune Bullous Skin Diseases
- Romani and Gypsy Studies
- Muscle and Compartmental Disorders
- Zoonotic diseases and public health
- Complement system in diseases
- Trace Elements in Health
- Mast cells and histamine
- IL-33, ST2, and ILC Pathways
- Acute Kidney Injury Research
- Intracerebral and Subarachnoid Hemorrhage Research
- Neurological and metabolic disorders
- Immune Cell Function and Interaction
- Vector-Borne Animal Diseases
- Otitis Media and Relapsing Polychondritis
Beaumont Hospital
2025
University Hospital Galway
2020-2022
University Hospital Limerick
2018-2021
Trinity College Dublin
2017-2021
Tallaght University Hospital
2018
RELX Group (United States)
2018
University of Limerick
2018
Kidney Centre
2016
University Hospital Waterford
2015
Background and objectives An environmental trigger has been proposed as an inciting factor in the development of anti-GBM disease. This multicenter, observational study sought to define national incidence disease during 11-year period (2003–2014) Ireland, investigate clustering cases time space, assess effect spatial variability on outcome. Design, setting, participants, & measurements We ascertained by screening immunology laboratories for instances positivity antibody renal...
A specific biomarker that can separate active renal vasculitis from other causes of dysfunction is lacking, with a kidney biopsy often being required. Soluble CD163 (sCD163), shed by monocytes and macrophages, has been reported as potential in diseases associated excessive macrophage activation. Thus, we hypothesized urinary sCD163 crescent macrophages correlates glomerular inflammation. We detected rat urine early the disease course experimental vasculitis. Moreover, microdissected...
Autosomal dominant polycystic kidney disease (ADPKD) is caused primarily by pathogenic variants in the PKD1 and PKD2 genes. Although type of ADPKD variant can influence severity, rare, hypomorphic have also been reported to modify severity or cause biallelic ADPKD. This study examines whether additional, potentially protein-altering, non-pathogenic contribute phenotypic outcomes. We investigated prevalence protein-altering patients with PKD1-associated The association between outcomes,...
Up to 70% of patients with ANCA-associated vasculitis (AAV) develop GN, 26% progressing ESKD. Diagnostic-grade and noninvasive tools detect active renal inflammation are needed. Urinary soluble CD163 (usCD163) is a promising biomarker vasculitis, but diagnostic-grade assay, assessment its utility in prospective diagnosis flares, evaluation proteinuric states needed.We assessed usCD163 assay (1) real-world cohort 405 AAV 121 healthy 488 non-AAV disease controls; (2) multicenter study 84...
Innate lymphocyte populations, such as innate lymphoid cells (ILCs), γδ T cells, invariant natural killer (iNK T) and mucosal-associated (MAIT) are emerging important effectors of immunity involved in various inflammatory autoimmune diseases. The aim this study was to assess the frequencies absolute numbers lymphocytes well conventional monocytes peripheral blood from a cohort anti-neutrophil cytoplasm autoantibody (ANCA)-associated vasculitis (AAV) patients. Thirty-eight AAV patients 24...
Objective The treatment of antineutrophil cytoplasmic antibody ( ANCA )–associated vasculitis AAV ) aims to suppress disease activity and prevent subsequent flare. This study sought explore the association early control with long‐term outcomes validate as an end point for future clinical trials in . Methods Data from 4 European Vasculitis Society inception (1995–2002) data on trial registry were studied. Clinical parameters patients at baseline 3 6 months after diagnosis assessed risk death...
The aetiology of ANCA-associated vasculitis (AAV) and triggers relapse are poorly understood. Vitamin D (vitD) is an important immunomodulator, potentially responsible for the observed latitudinal differences between granulomatous non-granulomatous AAV phenotypes. A narrow ultraviolet B spectrum induces vitD synthesis (vitD-UVB) via skin. We hypothesised that prolonged periods low ambient UVB (and by extension deficiency) associated with form disease increased risk relapse.Patients recruited...
<ns4:p><ns4:bold>Introduction:</ns4:bold> Intravenous therapy and medicines (IVTM) are the most common invasive interventions in use healthcare. Prescribed IVTM play an essential role treatment of illness, management chronic conditions maintaining health wellbeing. The intravenous (IV) route is administration concentrated medications (diluted or undiluted) directly into peripherally centrally inserted vascular access devices. Medication safety a key priority best practice standards required...
<ns4:p><ns4:bold>Introduction:</ns4:bold> Intravenous therapy and medicines (IVTM) are the most common invasive interventions in use healthcare. Prescribed IVTM play an essential role treatment of illness, management chronic conditions maintaining health wellbeing. The intravenous (IV) route is administration concentrated medications (diluted or undiluted) directly into peripherally centrally inserted vascular access devices. Medication safety a key priority best practice standards required...
Introduction: Intravenous therapy and medicines (IVTM) are the most common invasive interventions in use healthcare. Prescribed IVTM play an essential role treatment of illness, management chronic conditions maintaining health wellbeing. The intravenous (IV) route is administration concentrated medications (diluted or undiluted) directly into peripherally centrally inserted vascular access devices. Medication safety a key priority best practice standards required to guide safe preparation...
Tolvaptan is a vasopressin V2-receptor antagonist that inhibits cyst growth and slows the decline of kidney function in polycystic disease (PCKD). TEMPO 3:4 REPRISE Trials showed tolvaptan renal increase size. We aim to study prevalence Mid-West region Ireland their candidacy for therapy.